Overview of Caverject Impulse

Caverject Impulse is a specific, prescription-only injectable medication, manufactured by Pfizer, whose primary purpose is to facilitate the physiological processes necessary for a firm erection. Its unique design centers on the highly specific, targeted delivery of its single active component, Alprostadil (INN).

Property	Description
Active ingredient	Alprostadil (INN)
Form	Lyophilized powder for injection
Pharmacological class	Prostaglandin E₁ analog, Vasodilator
Common use	Addressing erectile dysfunction in adult males
Origin	Synthetic derivative (of Prostaglandin E₁)

What Type of Medicine is Caverject Impulse?

The active ingredient in this product is Alprostadil, which is a potent Prostaglandin E₁ analog and a direct-acting vasodilator. Alprostadil is an agent specifically approved for intracavernosal use in addressing erectile dysfunction. Alprostadil is a chemically synthesized form that is functionally identical to the naturally occurring Prostaglandin E₁ found within the human body.

Composition, Form, and Delivery System

Caverject Impulse is distinguished by its specialized, single-dose, dual-chamber syringe system, which contains the sterile, lyophilized powder for reconstitution. This form is a differentiating factor, as it solves the chemical instability of Alprostadil in a liquid state, requiring the powder and diluent to be mixed immediately prior to use. The product is administered exclusively via intracavernosal injection into the erectile tissue. This direct route of administration ensures the active agent exerts a high local concentration of its effects, maximizing the targeted vasodilatory action.

General Purpose of Alprostadil's Action

The fundamental action of this medicine is to establish the necessary hemodynamic and muscular conditions required for penile rigidity. By inducing immediate smooth muscle relaxation and rapid vasodilation in the cavernosal arteries, Alprostadil causes blood to rush into and become trapped within the erectile tissue. This process of local blood engorgement is the foundation of the medicine’s purpose, helping adult males achieve the required firmness for sexual activity.

Regulatory References

What side effects are possible with Caverject Impulse?

Possible Side Effects and Safety Information

The safety profile of Caverject Impulse (alprostadil) is documented in official government regulatory sources, classifying adverse reactions by frequency and organ system involvement.

Official Frequency Classification of Adverse Reactions

Classification	Examples of Reactions (by SOC)
Very Common (1/10)	Penile pain (Reproductive System)
Common (1/100 to < 1/10)	Penile fibrosis, injection site hematoma, headache
Uncommon (1/1,000 to < 1/100)	Prolonged erection, dizziness, hypotension, injection site swelling, urethral bleeding

Serious Adverse Reactions and Safety Constraints

The regulatory label documents serious adverse reactions. These include priapism, defined as an erection lasting six hours or more, which constitutes a medical emergency. Additionally, penile fibrosis, encompassing cavernosal scarring, angulation, and Peyronie’s disease, is listed as a serious concern, with risk noted to increase with long-term exposure.

Specific contraindications limit use based on pre-existing conditions. The medicine must not be used by individuals who have pre-existing anatomical deformation of the penis, such as severe angulation or fibrosis, or those with conditions that predispose them to priapism, including certain blood disorders like sickle cell disease. Furthermore, use is contraindicated in men with a penile implant or those for whom sexual activity is medically inadvisable due to underlying cardiovascular status.

Overdose and Emergency Response

The primary overdose concern documented for Caverject Impulse (alprostadil) is the localized effect resulting in a prolonged erection. According to regulatory documentation, a prolonged erection is defined as lasting between four and six hours, and this condition may escalate to priapism, which is an erection persisting for more than six hours.

Priapism is classified as a severe outcome and constitutes a medical emergency. Regulatory authorities mandate a clear instruction for patients regarding help-seeking: immediate medical assistance must be sought for any erection that persists longer than four hours. This strict time threshold is established because untreated priapism carries the official risk of irreversible penile tissue damage and permanent loss of potency.

In situations of potential overdose, management involves placing the patient under medical supervision until all systemic effects have resolved and penile detumescence has fully occurred. Supportive measures, such as established detumescent therapy, are employed to resolve the condition. While the primary effect is local, systemic manifestations like hypotension have also been noted in official warnings. No specific antidote is known for alprostadil overdose.

Therapeutic Uses of Caverject Impulse

What Caverject Impulse Treats: Main Uses and Benefits

Caverject Impulse (alprostadil) is a prescription medicine commonly used to help with symptom clusters that may become intense or disruptive, specifically symptoms that interfere with daily functioning linked to conditions presenting with localized discomfort. The core therapeutic focus is applied across domains where additional symptomatic support is needed.

Clinical scenarios for use involve the treatment of erectile dysfunction (ED) and serving as an adjunct to other diagnostic tests to help determine the underlying cause of the condition.

This supportive symptomatic assistance contributes to easing the overall symptom load for patients. The medicine may assist with maintaining functional stability when symptoms become more noticeable, particularly during phases of increased distress or discomfort.

“The application of this therapy is relevant when short-term symptomatic assistance is needed to help manage discomfort.”

This support assists with maintaining functional stability and supports general well-being during symptomatic phases.

Quick Fact: Relief for Symptoms that interfere with daily functioning

Regulatory References

FDA Prescribing Information for Caverject Impulse

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Caverject Impulse

Caverject Impulse (alprostadil) is a prescription medicine with strict population eligibility rules determined by regulatory agencies.

Category	Official Eligibility Status
Approved Population	Adult Males (aged 18 and older) for erectile dysfunction and diagnostic testing.
Gender/Age Exclusion	Contraindicated in women and pediatric patients (children and adolescents).

Absolute Contraindications

Use is prohibited in men with specific health and anatomical conditions that increase risk. Caverject Impulse must not be used by individuals with:

A known hypersensitivity to Alprostadil or any excipient.
Blood conditions that predispose to priapism (e.g., Sickle Cell Disease, Leukemia).
Anatomical penile abnormalities such as Peyronie's disease, angulation, cavernosal fibrosis, or a penile implant.
Underlying medical conditions, particularly cardiovascular status, that make sexual activity medically inadvisable.

Restricted or Conditional Use

Anticoagulant Therapy: Use requires caution, as men taking warfarin or heparin may have an increased risk of injection site bleeding.
Combination Use: Use with other intracavernosally injected vasoactive agents is not recommended, as safety and efficacy have not been established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Caverject Impulse (Alprostadil) focuses on pharmacodynamic risks related to its local, intracavernosal administration. This interaction profile differs from that of orally administered medicines, as the potential for pharmacokinetic drug-drug interactions between Alprostadil and other medicinal products has not been formally studied according to regulatory documents.

Documented Interaction Patterns

Interacting Substance Category	Documented Interaction Outcome
Other Vasoactive Agents (Intracavernously Injected)	Co-administration is not recommended; combination use may increase the risks of prolonged erection (priapism) and hypotension due to additive effects.
Anticoagulants (e.g., Warfarin, Heparin)	Co-administration may increase the propensity for injection site bleeding due to the combination of the medicine's properties and the injection procedure.

Regulatory Context and Constraints

The regulatory profile is structured around these specific, formally documented risks. The safety and efficacy of combining Caverject Impulse with other vasoactive agents have not been systematically established. Furthermore, official regulatory information contains no explicit mandatory timing rules for the separation of doses from other medicinal products, nor are there formally documented interactions with specific foods, alcohol, or herbal products.

Mechanism of Action

The mechanism of action for Caverject Impulse, based on its active ingredient Alprostadil, involves a physiological cascade that is confined to the local area of application and exhibits a quick onset.

Molecular Signaling for Smooth Muscle Relaxation

The process is initiated at the cellular level where Alprostadil acts as an agonist on mathbfEP2 and mathbfEP4 Prostanoid Receptors found on smooth muscle cells. This targeted interaction results in an increase in the local concentration of the second messenger cyclic AMP ( cAMP), which functions as a chemical signal to promote smooth muscle relaxation.

Cavernosal Vasodilation and Blood Inflow

The cAMP signal, mediated by Protein Kinase A, promotes the relaxation of the smooth muscle within the helicine arteries and sinusoidal spaces. This decrease in muscle tone causes vasodilation, permitting a significant volume of arterial blood to flow into and distend the corpus cavernosum.

Hemodynamic Veno-Occlusion (Blood Trapping)

As the blood-filled tissue expands within the limiting tunica albuginea, the volume mechanically compresses the small veins that normally drain the blood. This veno-occlusion mechanism is the final, essential step in the cascade, trapping the blood locally under pressure to sustain the physiological stiffness. The mechanism's physiological action is constrained by the structural integrity of the surrounding vascular and tissue anatomy.

Dosage and Administration Information

Administration and Official Usage Protocol

Caverject Impulse is administered exclusively by intracavernosal injection into the erectile tissue of the penis. The medicine is supplied as a lyophilized powder that must be reconstituted with the supplied diluent, typically bacteriostatic water for injection, immediately prior to use. This specialized preparation step is mandatory before the injection is administered.

Dosage Titration and Frequency Limits

The initiation of treatment follows a two-phase protocol. The initial dose titration is required to be performed under medical supervision in a healthcare setting to establish the lowest effective dose. This dose is defined as one that produces an erection suitable for intercourse that lasts no longer than one hour.

Etiology	Starting Dose (Intracavernosal)	Maximum Recommended Dose for Self-Injection
Vasculogenic, Psychogenic, or Mixed	2.5 mug	60 mug
Pure Neurogenic	1.25 mug	60 mug

For ongoing use, the established dose is administered intermittently, with a maximum frequency of no more than three times per week. A minimum interval of at least 24 hours must elapse between any two doses.

Procedural and Population Requirements

Proper use dictates that the patient must be thoroughly trained in the self-injection technique before using the medicine at home. The injection site must be located on the dorso-lateral aspect of the proximal third of the penis, and patients are instructed to alternate the side of the penis injected with each use. The product is not indicated for use in women or children.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Caverject Impulse

This overview summarizes the formal research studies conducted on the medicine, describing the types of evidence that exist and what remains uncertain, without providing any medical guidance or treatment advice.

Evidence for the Treatment of Erectile Dysfunction (ED)

Research exploring how symptoms change in men with ED has been conducted primarily through Randomized Controlled Trials (RCTs) and long-term open-label studies. RCTs involved controlled comparisons against an inactive injection (placebo). These studies examined functional outcomes used to define an erection suitable for sexual intercourse.

Study Designs and Measured Outcomes

Studies included rigorous double-blind and crossover trials, exploring short-term symptom changes over a few weeks. The studies monitored outcomes related to a functional erection that met a specific standard for rigidity and duration. The primary outcomes measured included functional outcomes, such as scores from the International Index of Erectile Function (IIEF).

Research on Use as a Diagnostic Tool

Research also explored the medicine's use as an acute, in-office diagnostic tool. Studies examined the short-term physiological response in conjunction with diagnostic procedures, such as penile Doppler ultrasound. The injection was used to facilitate an erection for concurrent measurement of blood flow through the cavernosal arteries.

Long-Term Studies and Follow-up Durations

Formal research explored short-term symptom changes, but longer-term open-label studies extended only up to six months. Research focusing on outcomes over many years is lacking, meaning that evidence contributing to understanding symptom patterns over a lifetime of use is still emerging.

Evidence in Specific Patient Groups

Studies evaluated use in subgroups whose conditions involved functional limitations, such as men with diabetes and neurogenic ED (e.g., due to spinal cord injury). While these groups were included, results apply only to the populations studied, and evidence quality varies.

What Remains Uncertain About the Research

Several key limitations are documented: high rates of patient discontinuation (dropouts) were observed in long-term studies, which introduces uncertainty regarding patterns of use. Comparative evidence is lacking for how patient-reported satisfaction compares to alternative therapies. Research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Caverject Impulse (FAQ)

Q: Does Caverject Impulse cause a spontaneous erection or one that requires stimulation?

According to official product information, Caverject Impulse is indicated for use prior to sexual activity. The goal of using the medicine is to achieve an erection that is suitable for intercourse. This suggests that the dose is intended to support the physiological processes necessary for sexual activity.

Q: What is the average duration of the erection after using Caverject Impulse?

Regulatory documents state that the lowest effective dose is defined as one that results in an erection suitable for intercourse that does not exceed a duration of one hour. This one-hour duration is specified in the official information as the maximum duration for an erection achieved during the dose-finding process.

Q: Is it normal to feel a mild burning or pain after the injection?

Official data on adverse reactions lists penile pain as a very common side effect, meaning it was reported by more than 10% of patients in clinical studies. While the specific sensation of 'burning' may vary, some injection site discomfort or pain has been frequently reported as an adverse reaction.

Q: Does the injection needle for Caverject Impulse hurt a lot?

The device uses a superfine (29 gauge) needle for administration. The importance of proper patient training in the self-injection technique is highlighted in official information to help minimize potential risks, such as needle breakage.

Q: Is Caverject Impulse considered a cure for erectile dysfunction?

The official product labeling indicates that Caverject Impulse is a treatment for erectile dysfunction and is also used as an adjunct to certain diagnostic tests. The medicine is not classified as a cure for the underlying causes of erectile dysfunction.

Q: Are there any foods or drinks that interfere with Caverject Impulse?

According to regulatory documents, formal studies specifically examining pharmacokinetic drug-drug interactions between the medicine and foods, alcohol, or herbal products have not been formally conducted. Official documentation does not provide advice regarding diet or other substances, which should be discussed with a healthcare professional.

Q: Can Caverject Impulse be used more than once a day?

Official dosing rules set a maximum frequency for use. The recommended frequency of injection is no more than three times weekly, with an interval of at least 24 hours required between each dose.

Q: Why is proper mixing of the solution so important?

The medicine is supplied as a lyophilized powder and must be reconstituted, or mixed, with the diluent immediately prior to use. The solution must be properly prepared prior to use to ensure the correct, fully dissolved dose is available.

Q: Are there different strengths or versions of Caverject Impulse?

Yes, Caverject Impulse is available in pre-filled syringe systems of different strengths, such as 10 mcg and 20 mcg. These varying concentrations allow for the accurate measurement and delivery of different dosages once the solution has been prepared.

Q: How do I know where exactly to inject Caverject Impulse?

Official guidance states that a healthcare professional provides full instruction and training on the correct self-injection technique. The site is specified as the dorso-lateral aspect (the top-side) of the proximal third of the penis.

Q: Can using Caverject Impulse affect sperm or fertility?

While the medicine's main action is local, official information reminds users that the product will not protect a partner from pregnancy. Questions regarding fertility and contraception should be directed to a healthcare professional.

Q: Are there any long-term effects of using this medicine regularly?

Official labeling notes that penile fibrosis, which is scarring of the erectile tissue, has occurred, and the risk is noted to increase with long-term exposure. Official information states that regular physical examination of the penis may be recommended to detect any signs of fibrosis.

Q: What if I accidentally inject too little of the mixed solution?

During the initial phase of treatment, the dose is established under physician supervision to find the lowest effective amount. If the initial injection only results in a partial response, another dose may be administered within one hour during that titration phase. Any decision regarding subsequent dosing should be made by a healthcare professional.

Q: How should Caverject Impulse be stored before mixing and after?

The unreconstituted powder should be stored at controlled room temperature, but should not be frozen. Once mixed, the reconstituted solution must be used within 24 hours and can be stored at room temperature or refrigerated up to 25 C.

Q: Why does the solution need to be clear before injection?

The solution must be gently agitated to ensure the powder is fully dissolved. Official instructions specify that the solution should be clear and free of particles. A cloudy or particulate solution should not be used, as this may indicate improper preparation or a defect.

Q: How often do people need to adjust their dose after starting Caverject Impulse?

It is recommended that patients visit the prescribing physician's office every three months to assess the efficacy and safety of the ongoing therapy. This schedule allows for the ongoing assessment of efficacy and safety, and provides the opportunity for dose adjustment as needed.

Q: What should a partner know about a man using Caverject Impulse?

Partners should be aware that the injection can cause a small amount of bleeding at the injection site, which could potentially increase the risk of transmitting sexually transmitted diseases (STDs). Additionally, the medicine does not prevent pregnancy.

How should Caverject Impulse be stored and disposed of?

How to Store and Dispose of Caverject Impulse?

The official storage and disposal requirements for Caverject Impulse are defined by regulatory labeling to maintain the product's stability and ensure safety.

Storage Conditions

Product State	Temperature Requirement	Stability Constraint
Unreconstituted Powder	Controlled Room Temperature (20 C to 25 C)	Do not freeze
Reconstituted Solution	2 C to 25 C (36 F to 77 F)	Use within 24 hours

All medicine and injection supplies must be kept out of the sight and reach of children. The product should be stored in its original carton.

Disposal Requirements

Used needles and syringes must be placed immediately into an FDA-cleared sharps disposal container. It is strictly prohibited to dispose of loose needles and syringes in household trash or to flush them down the toilet. Any unused or expired medicine must be disposed of according to local regulatory guidelines.

Caverject Impulse